Pyruvate kinase M2 (Tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review;Pyruvatkinase M2 (Tumor M2-PK) im stuhl als screeningparameter für kolorektale neoplasien. Eine übersicht über bisher publizierte daten

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 12, 2005, Pages 1313-1317

  Ewald, Nils ^a   Toepler, M ^a   Akinci, A ^a   Kloer, H U ^a   Bretzel, R G ^a   Hardt, P D ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Colorectal cancer; Stool; Tumor M2 PK; Tumor screening

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

CANCER SCREENING; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENTERITIS; ENZYME ASSAY; EPITHELIUM CELL; FECES ANALYSIS; GENETIC ANALYSIS; GERMANY; HEALTH CARE SYSTEM; HUMAN; LEUKOCYTE; OCCULT BLOOD; REVIEW; SCREENING TEST; VALIDATION PROCESS;

CLINICAL TRIALS; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; NEOPLASM PROTEINS; PYRUVATE KINASE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 29944447700     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858657     Document Type: Review

References (44)

1. Ries LAG, Kocary CL, Hankey BF et al. SEER cancer statistic review: 1973-1994. Bethesda: MD National Cancer Institute, 1997
2. Lamberti C, Sauerbruch T. Frühdiagnostik kolorektaler Tumorleiden. Internist 2005; 46: 401-410
3. Towler B, Irwing L, Glaziou P et al. A systematic review of the effects of screening for colorectal cancer using the fecal occult blood test, hemoccult. BMJ 1998; 317: 559-565
4. Winanwer SJ, Flehinger BJ, Schottenfeld D et al. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85: 1311-1318
5. Collins JF, Lieberman DA, Durbin TE et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Veterans Affairs Cooperative Study #380 Group. Ann Intern Med 2005; 142: 81-85
6. Niv Y, Sperber AD. Sensitivity, specificity, and predivtive value of fecal occult blood testing (hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Am J Gastroenterol 1995; 90: 1947-1977
7. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis? Nat Rev Cancer 2005; Mar; 5: 199-209
8. Duranyi N, Joseph J, Campo E et al. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 1997; 75: 969-977
9. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 1997; 29: 315-330
10. Staal GE, Riiksen G. The role of red cell aging in the diagnosis of glycolytic enzyme defects. Adv Exp Med Biol 1991; 307: 239-249
11. Mazurek S, Grimm H, Oehmke M et al. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 2000; 20: 5151-5154
12. Saheki S, Harada K, Sanno Y et al. Hybrid isozymes of rat pyruvate kinase. Their subunit structure and developmental changes in the liver. Biochem Biophys Acta 1978; 526: 116-128
13. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003; 23: 1149-1154
14. Eigenbrodt E, Reinacher M, Scheefers-Borchel U et al. Double role for pyruvate kinase type M2 in expansion of phosphometabolite pools found in tumor cells. Critical Reviews in Oncogenesis 1992; 3: 91-115
15. Cerwenka H, Aigner R, Bacher H et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999; 19: 849-851
16. Mazurek S, Zwerschke W, Janssen-Dürr P et al. Metabolic cooperation between different oncogenes durin cell transformation: interaction between activated ras and HPV-16E7. Oncogene 2001; 20: 6891-6898
17. Eigenbrodt E, Mazurek S, Friis RR. Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Bannasch P, Kanduc D, Papa S, Tager JM (Hrsg). Cell Growth and Oncogenesis. Basel: Birkhäuser Verlag, 1998:15-30
18. Zwerschke W, Mazurek S, Massimi P et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 onco-protein. Proc Natl Acad Sci USA 1999; 96: 1291-1296
19. Kress S, Stein A, Maurer P et al. Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol 1998; 124: 315-320
20. Dehm S, Senger MA, Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 2001; 487: 367-371
21. Iravani S, Mao W, Fu L et al. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest 1998; 78: 365-371
22. Hardt PD, Ngoumou BK, Rupp J et al. Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20: 4965-4968
23. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003; 23: 5089-5093
24. Hardt PD, Toepler M, Ngoumou B et al. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23: 851-853
25. Seufferlein T, Adler G. Früherkennung kolorektaler Karzinome. Onkologe 2002; 8: 1080-1088
26. Alquist DA, McGill DB, Schwartz S et al. Fecal blood levels in health and disease. N Engl J Med 1985; 312: 1422-1428
27. Towler BP, Irwig L, Glasziou P et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2 1998, CD001216
28. Young GP, St John DJ. Selecting an occult blood test for use as a screening tool for large bowel cancer. Front Gastrointest Res 1991; 18: 135-156
29. Macrae FA, St John DJ. Relationship between patterns of bleeding and Haemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-898
30. Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-1371
31. Mandel JS, Church TR, Ederer F et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437
32. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471
33. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50: 29-32
34. Hardcastle JD et al. Randomised controlled trial of faecal occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477
35. Mandel JS et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2002; 343: 1603-1607
36. Frattini M, Balestra D, Pilotti S et al. Tumor location and detection of k-ras mutations in stool from colorectal cancer patients. J Natl Cancer Inst 2003; 95: 72-73
37. Eguchi S, Kohara N, Komuta K et al. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996; 77: 1707-1710
38. Traverso G et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311-320
39. Traverso G et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359: 403-404
40. Hardt PD, Mazurek S, Toepler M et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-984
41. Naumann M, Schaum B, Oremek GM et al. Faecal pyruvate kinase type M2 - a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004; 129: 1806-1807
42. Haug U, Rothenbacher D, Hardt PD et al. Tumor M2PK: a promising method for colorectal cancer screening. J Cancer Res Clin Oncol 2004; 130: 172
43. Vogel T, Driemel C, Hauser A et al. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130: 872-877
44. Koss K, Maxton D, Jankowski J. The potential use of fecal dimeric M2 pyruvate kinase (tumour M2PK) in screening for colorectal cancer. Gut 2005; 54: 20